{"entity":{"id":"nct04585750","kind":"trial","name":"The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)","aka":["PYNNACLE"],"tldr":"A phase 1/2 trial of Pembrolizumab in metastatic cancer and ovarian cancer, run by PMV Pharmaceuticals, Inc, now recruiting.","summary":"The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) is a phase 1/2 interventional study registered as NCT04585750 by PMV Pharmaceuticals, Inc, with 300 participants planned, started 2020-10-29 and due to reach its primary completion in 2026-12-15. Interventions recorded: rezatapopt, pembrolizumab. Conditions listed: Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04585750","url":"https://clinicaltrials.gov/study/NCT04585750"}],"tags":["ctgov-ingest"],"related":[],"cancers":["metastatic-cancer","ovarian","endometrial","prostate","colorectal","endometrial-p53-abnormal"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-nct04585750-n-engl-j-med-2026"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04585750","phase":"1/2","setting":"A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)","sponsor":"PMV Pharmaceuticals, Inc","started":"2020-10-29","startedType":"actual","enrolled":300,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04585750/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"endometrial-p53-abnormal","kind":"cancer","name":"p53-abnormal endometrial cancer, including uterine serous carcinoma","route":"/cancers/endometrial-p53-abnormal/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"paper":[{"id":"paper-nct04585750-n-engl-j-med-2026","kind":"paper","name":"Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C-Mutated Tumors","route":"/key-papers/paper-nct04585750-n-engl-j-med-2026/"}]}}